ExodusPoint Capital Management’s Viking Therapeutics VKTX Stock Holding History

ExodusPoint Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.48M	Sell	137,100 -189,300	-58%	-$6.08M	0.04%	478
2025 Q4	$11.5M	Buy	326,400 +306,400	+1,532%	+$10.9M	0.09%	218
2025 Q3	$524K	Hold	20,000	–	–	0.01%	1169
2025 Q2	$531K	Hold	20,000	–	–	﹤0.01%	1136
2025 Q1	$484K	Sell	20,000 -294,300	-94%	-$9.3M	﹤0.01%	1115
2024 Q4	$12.7M	Buy	314,300 +163,200	+108%	+$9.31M	0.09%	216
2024 Q3	$9.58M	Sell	151,100 -123,400	-45%	-$7.24M	0.06%	245
2024 Q2	$14.5M	Buy	274,500 +245,100	+834%	+$16.1M	0.1%	180
2024 Q1	$2.42M	Buy	+29,400	New	+$1.31M	0.02%	626

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

ExodusPoint Capital Management's VKTX Position: Q1 2026 in Review

ExodusPoint Capital Management reduced its Viking Therapeutics (VKTX) stake by 90% in Q1 2026, selling an estimated $21M and leaving 69,627 shares worth $2.27M. The position accounts for 0.02% of the portfolio, ranked #742.

ExodusPoint Capital Management first reported a position in VKTX in Q2 2019 and has held it in 19 quarters since. The position peaked at $25.4M in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

ExodusPoint Capital Management held 69,627 shares of Viking Therapeutics worth $2.27M as of Q1 2026.
ExodusPoint Capital Management sold 652,572 Viking Therapeutics shares in Q1 2026, an estimated $21M.
Viking Therapeutics made up 0.02% of ExodusPoint Capital Management's portfolio in Q1 2026, its #742 holding.
ExodusPoint Capital Management first reported a position in Viking Therapeutics in Q2 2019 and has held it in 19 quarters since.
ExodusPoint Capital Management's Viking Therapeutics position peaked at $25.4M in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on ExodusPoint Capital Management's 13F filing for Q1 2026, filed 14 May 2026.